Linked Data API

Show Search Form

Search Results

78009
star this property registered interest false more like this
star this property date less than 2014-07-15more like thismore than 2014-07-15
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Radiotherapy more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, for what reason none of the £42 million his Department has made available for increasing the use of radiotherapy is to be spent on treating cancer patients with Stereotactic Ablative Radiotherapy this year. more like this
star this property tabling member constituency Wells more like this
star this property tabling member printed
Tessa Munt remove filter
star this property uin 205834 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-07-22more like thismore than 2014-07-22
unstar this property answer text <p>In July 2011, the National Radiotherapy Implementation Group concluded that current evidence supports treatment withstereotactic ablative radiotherapy (SABR) for only a small number of patients. The evidence supports its use in the treatment of early stage lung cancers for patients who are unsuitable for surgery (approximately 1,000 per annum).</p><p> </p><p>NHS England recognises the positive clinical impact that its national policy on SABR for the treatment of early non-small cell lung cancer has had. It is currently examining the potential use of SABR in patients with oligometastatic disease – where a cancer is in the early stages of spreading.</p><p> </p><p>NHS England is also currently undertaking a review of stereotactic radiosurgery (SRS) and SABR for intracranial conditions to establish what the national demand is in line with its national clinical commissioning policies on SRS and SABR, and what the national capacity requirements are for this specialised treatment. Following the review it is planned that a final decision will be taken by the Specialised Commissioning Oversight Group in October 2014.</p><p> </p><p>Later this year, the Radiotherapy Clinical Reference Group will review its current policy position on SABR to assess whether there is new evidence to recommend its use on other conditions. It is important to ensure that treatments commissioned are supported by robust evidence of their benefit to patients.</p><p> </p>
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
remove filter
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
4089
unstar this property label Biography information for Tessa Munt more like this